secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-09-17T23:59:59+00:00
Accession:  0001140361-25-035251
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma finalizes Dr. Patel separation; consulting through Dec 2026 with $582K retainer
--------------------------------------------------------------------------------

- Dr. Kinnari Patel receives $482,040 lump-sum severance (10 months salary) and $30,045 healthcare allowance.
- She stays on paid garden leave through Dec 31, 2025; then consulting until Dec 31, 2026 for $582,156 retainer.
- Patel retains restricted stock units and options during the consulting period under existing plans.
- Accrued PTO payout of $102,480; 2025 bonus eligibility subject to company performance.
- Payments conditioned on release of claims, non-disparagement, and restrictive covenant compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125035251/0001140361-25-035251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125035251/ef20055707_form8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-035251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer